Wave Life Sciences. has filed a patent for oligonucleotides and compositions useful for adenosine modification. The invention includes methods for treating conditions that can benefit from adenosine modification. GlobalData’s report on Wave Life Sciences gives a 360-degree view of the company including its patenting strategy. Buy the report here.

Smarter leaders trust GlobalData


Data Insights Wave Life Sciences Ltd - Company Profile

Buy the Report

Data Insights

The gold standard of business intelligence.

Find out more

According to GlobalData’s company profile on Wave Life Sciences, siRNA gene silencing was a key innovation area identified from patents. Wave Life Sciences's grant share as of January 2024 was 24%. Grant share is based on the ratio of number of grants to total number of patents.

Oligonucleotides for adenosine modification in treating diseases

Source: United States Patent and Trademark Office (USPTO). Credit: Wave Life Sciences Ltd

A patent application (Publication Number: US20240026358A1) has been filed for an oligonucleotide with specific structural features designed to modify target adenosines in nucleic acids. The oligonucleotide comprises a first domain and a second domain, with the first domain containing 2'-F blocks and separating blocks. When this oligonucleotide interacts with a target nucleic acid containing a target adenosine, the adenosine is converted to inosine. The patent claims cover various aspects of the oligonucleotide's structure, including the number of modified sugars and internucleotidic linkages, as well as the length and composition of the domains.

Furthermore, the patent application describes methods for preparing, characterizing, and using the oligonucleotide to modify target adenosines in nucleic acids. These methods involve contacting the oligonucleotide with a target nucleic acid and an adenosine deaminase enzyme to induce the desired modifications. The application also includes claims related to pharmaceutical compositions containing the oligonucleotide, as well as methods for preventing or treating conditions associated with specific mutations, such as G to A mutations. Overall, the patent application outlines a novel oligonucleotide design and associated methods for targeted nucleic acid modification with potential therapeutic applications.

To know more about GlobalData’s detailed insights on Wave Life Sciences, buy the report here.

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies